SOURCE: NuPathe Inc.

NuPathe Inc.

October 07, 2010 16:15 ET

NuPathe Appoints Michael Marino as General Counsel

CONSHOHOCKEN, PA--(Marketwire - October 7, 2010) -  NuPathe Inc. (NASDAQ: PATH), a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces the appointment of Michael Marino as Vice President, General Counsel and Corporate Secretary.

Jane H. Hollingsworth, chief executive officer, said, "Michael brings a strong mix of legal, business, and management experience to NuPathe. We are delighted to welcome Michael to the management team and look forward to his contributions."

Mr. Marino has over 9 years of top law firm experience. Prior to joining NuPathe, Mr. Marino was a Senior Associate in the Corporate Law Department at Morgan, Lewis and Bockius LLP, in Philadelphia, PA. While there, he advised both public and private companies in connection with securities offerings, financings, mergers and acquisitions, strategic partnerships, SEC compliance, corporate governance, and other corporate matters. Prior to Morgan, Lewis and Bockius, Mr. Marino was an Associate in the Corporate Law Department at WilmerHale LLP in Boston, MA and an auditor at Arthur Andersen LLP.

Mr. Marino earned a B.S. in Accountancy from Villanova University and his J.D. from Boston College Law School.

About NuPathe

NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. NuPathe's most advanced product candidate, Zelrix™, is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan, the most widely prescribed migraine medication, through the skin in a controlled manner using its proprietary SmartRelief™ technology.

In addition, NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. For more information, please visit NuPathe's website at www.nupathe.com.

Contact Information

  • Contact Information:

    Keith A. Goldan
    Vice President and Chief Financial Officer
    (484) 567-0130

    John Woolford
    Westwicke Partners, LLC
    (443) 213-0506